Table 2.
Demographic information for target sample
| HC | FR | SCZ | ||
|---|---|---|---|---|
| Variables | (n = 146) | (n = 56) | (n = 130) | P values (F or χ2) |
| Age (y) | 37.2 ± 14.1 | 56.8 ± 15.6 | 42.9 ± 13.1 | 2.49 × 10 –21 (55.0) |
| Gender (male/female) | 97/49 | 18/38 | 50/80 | 3.22 × 10 –7 (30.0) a |
| Education (y) | 16.1 ± 2.4 | 12.8 ± 2.1 | 12.6 ± 2.2 | 2.05 × 10 –32 (91.8) |
| Estimated premorbid IQ | 108.5 ± 7.7 | 99.7 ± 9.1 | 98.7 ± 10.4 | 5.38 × 10 –18 (45.0) |
| CPZ-eq. (mg/d) | 0 | 0 | 509.6 ± 512.7 | – |
| Age at onset (y) | – | – | 26.9 ± 10.6 | – |
| DOI (y) | – | – | 15.8 ± 11.3 | – |
| PANSS positive symptoms | – | – | 16.0 ± 6.2 | – |
| PANSS negative symptoms | – | – | 17.8 ± 6.8 | – |
Abbreviations: CPZ-eq., chlorpromazine equivalent of total antipsychotics; DOI, duration of illness; FR, first-degree relative; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; SCZ, schizophrenia. The mean ± SD and P values are shown. Complete demographic information was not obtained for all participants (estimated premorbid IQ in HCs, n = 145). Continuous variables were analyzed using parametric ANOVA. The difference in categorical variables was analyzed using Pearson’s χ2 test.
a χ 2 test.